Companies · Biotechnology

CHF Solutions, Inc.

EDEN PRAIRIE · Biotechnology

Diligence memoA one-page analyst read on CHF Solutions, Inc. — recommendation, valuation, rhythm, risks.
$33.0M
Total raised · real
17
Rounds
2.3×
Latest step-up
Top 25%
Sector rank · raised
Series A
Latest stage · inferred · Wed Nov 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

CHF Solutions, Inc. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.38× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
  • Issuer reports $5M–$25M revenue while modeled below niche peers.
Quiet
  • Last raise 20 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

CHF Solutions, Inc. is one of 4291 Biotechnology companies tracked from EDEN PRAIRIE. By capital raised it ranks in the upper tier (ahead of 76% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$5M–$25M
Issuer revenue
Rule 506(b)
Reg D exemption
9
Investors (latest)
2024-11-06
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2010-11-15 Raised $3.5M (real) Modeled valuation $155M (est)Seed2010Series A · 2011-07-27 Raised $5.0M (real) Modeled valuation $180M (est)Series A · 2012-02-08 Raised $2.1M (real) Modeled valuation $76M (est)Series A2012Series A · 2012-09-07 Raised $700K (real) Modeled valuation $25M (est)Series A · 2013-01-15 Raised $1.5M (real) Modeled valuation $54M (est)Series A2013Series A · 2015-02-18 Raised $360K (real) Modeled valuation $13M (est)Series A · 2016-07-20 Raised $3.5M (real) Modeled valuation $125M (est)Series A2016Series A · 2016-08-05 Raised $950K (real) Modeled valuation $34M (est)Series A · 2016-10-30 Raised $3.6M (real) Modeled valuation $130M (est)Series A2016Series A · 2017-01-11 Raised $200K (real) Modeled valuation $7.2M (est)Series A · 2017-02-15 Raised $564K (real) Modeled valuation $20M (est)Series A2017Series A · 2019-10-25 Raised $663K (real) Modeled valuation $24M (est)Series A · 2019-11-06 Raised $1.4M (real) Modeled valuation $49M (est)Series A2019Series A · 2020-03-23 Raised $1.2M (real) Modeled valuation $45M (est)Series A · 2020-04-01 Raised $2.2M (real) Modeled valuation $80M (est)Series A2020Series A · 2020-05-05 Raised $1.7M (real) Modeled valuation $61M (est)Series A · 2024-11-06 Raised $3.8M (real) Modeled valuation $17M (est)Series A2024Cumulative $33M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.5M · 2010
Series A$5.0M · 2011
Series A extension$2.1M · 2012
Series A extension$700K · 2012
Series A extension$1.5M · 2013
Series A extension$360K · 2015
Series A extension$3.5M · 2016
Series A extension$950K · 2016
Series A extension$3.6M · 2016
Series A extension$200K · 2017
Series A extension$564K · 2017
Series A extension$663K · 2019
Series A extension$1.4M · 2019
Series A extension$1.2M · 2020
Series A extension$2.2M · 2020
Series A extension$1.7M · 2020
Series A extension$3.8M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$17.0M
Base estimate est.
$4.2M
Conservative case
$34.0M
Upside case
$17.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $155.4M · 2010-11-152010Series A · modeled $179.7M · 2011-07-27Series A · modeled $76.4M · 2012-02-08Series A · modeled $25.3M · 2012-09-07Series A · modeled $54.2M · 2013-01-15Series A · modeled $13.0M · 2015-02-18Series A · modeled $125.4M · 2016-07-20Series A · modeled $34.3M · 2016-08-05Series A · modeled $130.1M · 2016-10-30Series A · modeled $7.2M · 2017-01-11Series A · modeled $20.4M · 2017-02-15Series A · modeled $24.0M · 2019-10-25Series A · modeled $49.4M · 2019-11-06Series A · modeled $45.1M · 2020-03-23Series A · modeled $80.5M · 2020-04-01Series A · modeled $61.5M · 2020-05-05Series A · modeled $17.0M · 2024-11-062024
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
1.6 yr
Elapsed time used
1.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
10 mo
Avg between rounds
$2.4M/yr
Capital velocity
15.6 yr
On record since
2010
First round
17
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.6× above median
This company$33.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.7× of median
This company$3.8M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$17.0M
Sector median$64.2M

Raised more than 76% of sector peers (real $). Modeled value above 26% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #248 of 303.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.0M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $215.9M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $206.8M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.3M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $188.9M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.0M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.7M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $183.8M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.2M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.2M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.1M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $168.8M (est)CHF Solutions, Inc. (this company) Raised $33.0M · modeled $17.0M (est)CHF Solutions, Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.0M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$215.9M4.87×
Adient Medical, Inc.Series A$18.2M$206.8M4.67×
Entegrion IncSeries A$22.7M$191.3M4.32×
BCD Bioscience, Inc.Series A$16.4M$188.9M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.0M4.20×
MicroByre, Inc.Series A$16.1M$185.7M4.19×
Cardiac Insight, Inc.Series A$38.1M$183.8M4.15×
Cardiac Implants LLCSeries A$13.5M$178.2M4.02×
Abintus Bio, Inc.Series A$13.7M$177.2M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.1M3.98×
Mazen Animal Health Inc.Series A$13.5M$168.8M3.81×
CHF Solutions, Inc. this companySeries A$33.0M$17.0M0.38×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.5M2010-11-15$17.5M$155.4M85%
Series A$5.0M2011-07-27$22.6M$179.7M85%
Series A$2.1M2012-02-08$9.6M$76.4M85%
Series A$700K2012-09-07$3.2M$25.3M85%
Series A$1.5M2013-01-15$6.8M$54.2M85%
Series A$360K2015-02-18$1.6M$13.0M85%
Series A$3.5M2016-07-20$15.8M$125.4M85%
Series A$950K2016-08-05$4.3M$34.3M85%
Series A$3.6M2016-10-30$16.4M$130.1M90%
Series A$200K2017-01-11$909K$7.2M90%
Series A$564K2017-02-15$2.6M$20.4M90%
Series A$663K2019-10-25$3.0M$24.0M90%
Series A$1.4M2019-11-06$6.2M$49.4M90%
Series A$1.2M2020-03-23$5.7M$45.1M90%
Series A$2.2M2020-04-01$10.1M$80.5M90%
Series A$1.7M2020-05-05$7.7M$61.5M90%
Series A$3.8M2024-11-06$17.5M$17.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.5M2010-11-15
    • First recorded raise — entered as Seed.
    • 7 investors on this round.
  2. Series A$5.0M2011-07-27
    • Raised 8 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 9 investors on this round.
  3. Series A$2.1M2012-02-08
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 2.4× smaller than the prior — bridge or down round.
    • 4 investors on this round.
  4. Series A$700K2012-09-07
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 3.0× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  5. Series A$1.5M2013-01-15
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 2.1× larger than the prior — scaling up.
    • 1 investor on this round.
  6. Series A$360K2015-02-18
    • Raised again after 25 mo — slower than the ~14 mo sector norm.
    • Round 4.2× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 2 investors on this round.
  7. Series A$3.5M2016-07-20
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 9.6× larger than the prior — scaling up.
    • 2 investors on this round.
  8. Series A$950K2016-08-05
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 3.7× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  9. Series A$3.6M2016-10-30
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 3.8× larger than the prior — scaling up.
    • 2 investors on this round.
  10. Series A$200K2017-01-11
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 18.0× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  11. Series A$564K2017-02-15
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 2.8× larger than the prior — scaling up.
    • 2 investors on this round.
  12. Series A$663K2019-10-25
    • Raised again after 32 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
  13. Series A$1.4M2019-11-06
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× larger than the prior — scaling up.
    • 3 investors on this round.
  14. Series A$1.2M2020-03-23
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 4 investors on this round.
  15. Series A$2.2M2020-04-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× larger than the prior — scaling up.
    • 4 investors on this round.
  16. Series A$1.7M2020-05-05
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 4 investors on this round.
  17. Series A$3.8M2024-11-06
    • Raised again after 54 mo — slower than the ~14 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
    • 9 investors on this round.
Intelligence
2025 ~Q3
Modeled next raise · ~10mo cadence
$8.7M
Modeled next size est.range $5.7M$13.9M
2.3×
Last step-up
$2.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Paul Buckman9 other2012-09
David A. Rosa4 other2010-11
David Rosa4 other2012-09
John L. Erb4 other2013-01
Jon Salveson4 other2016-08
Gregory D. Waller3 other2013-01
JEFFREY S. MATHIESEN3 other2013-01
John Erb2 other2012-09
Mark Harvey2 other2012-09
Paul A Buckman2 other2011-07
Warren Watson2 other2016-08
William Peters2 other2012-09
Donal O'Dwyer1 other2012-09
Geoffrey Brooke1 other2012-09
Gregory Waller1 other2012-09
Jeffrey Mathiesen1 other2012-09
Kevin Bassett1 other2012-09
Molly Wade1 other2016-08
Paul L. Buckman1 other2016-07
Paul R. Buckman1 other2013-01
Warren S. Watson1 other2013-01
Archelle L. Georgiou, M.D.2024-11
Brian E. Brown2015-02
Claudia Drayton2016-08
Registry & provenance

CHF Solutions, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1506492
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
NEUROONE MEDICAL TECHNOLOGIES CorpBiotechnologySeries A$21.2M$1.4Mnetwork3 shared operators · same sector · same stage
Biotricity Inc.BiotechnologySeries A$10.6M$6.0Mnetwork2 shared operators · same sector · same stage
JustRight Surgical, LLCBiotechnologySeries A$31.9M$198.8Mnetwork1 shared operator · same sector · same stage
BioRestorative Therapies, Inc.BiotechnologySeries A$19.8M$4.0Mnetwork1 shared operator · same sector · same stage
Pathway Therapeutics, Inc.BiotechnologySeries A$16.9M$14.5Mnetwork1 shared operator · same sector · same stage
InSitu Biologics, IncBiotechnologySeries A$13.9M$10.7Mnetwork1 shared operator · same sector · same stage
Pathway Medical Technologies IncBiotechnologySeries A$9.9M$359.1Mnetwork1 shared operator · same sector · same stage
Aortica CorpBiotechnologySeries A$8.0M$37.1Mnetwork1 shared operator · same sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Chroma Medicine, Inc.BiotechnologySeries D+$2.3B87%
ChromaDex Corp.BiotechnologySeries B$46.9M87%
Chemical Solutions Group, LLCBiotechnologySeries A$361.5M87%
CRS Bio, Inc.BiotechnologySeries A$303.7M87%
Chromocare Holdings, LLCBiotechnologyPre-Seed$27.6M86%
ChromaCode, Inc.BiotechnologySeries B$21.4M86%
Gene Solutions LlcBiotechnologySeries A$192.7M85%
ChromaTan Inc.BiotechnologySeed$120.8M85%
Frequently asked
How much funding has CHF Solutions, Inc. raised?
CHF Solutions, Inc. has raised approximately $33.0M in disclosed capital across 17 recorded financing rounds, aggregated from public filings.
What is CHF Solutions, Inc.'s estimated valuation?
Provath's modeled valuation for CHF Solutions, Inc. is approximately $17.0M (modeled range $4.2M–$34.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is CHF Solutions, Inc. at?
CHF Solutions, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Nov 06.
What does CHF Solutions, Inc. do and where is it based?
CHF Solutions, Inc. operates in the Biotechnology sector, based in EDEN PRAIRIE.
Explore related

See where CHF Solutions, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at CHF Solutions, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.